10:06 AM EDT, 07/30/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) said Wednesday it has entered into a

entered into an exclusive global license deal with CSPC Pharmaceutical Group to develop, manufacture, and commercialize SYH2086, a preclinical candidate designed to treat metabolic dysfunction-associated steatohepatitis.

CSPC will receive an upfront payment of $120 million and is eligible to receive up to $2 billion in milestone payments, as well as royalties on net sales, Madrigal said.

The transaction, expected to close in Q4, backs Madrigal's strategy to develop combination treatments for MASH, built around its Rezdiffra drug, it added.

The company said it plans to start clinical development of the drug in H1 of 2026.

CSPC may develop and commercialize other oral GLP-1 agonists in China, subject to certain conditions, Madrigal said.

Price: 296.60, Change: +2.20, Percent Change: +0.75